增大性甲状腺微小乳头状癌生长活性的动力学分析
研究纳入824例2005至2011年开始主动监测的甲状腺微小乳头状癌(PMC)患者,中位随访6.04年,分析肿瘤增大前后生长活性变化。基于最大径和体积的10年无增大生存率分别为86.9%和54.9%。增大后肿瘤倍增速率(TDR)中位数显著低于增大前,多数肿瘤增大后生长活性下降,提示增大后立即手术可能为时过早。
要点
- PMC增大后多数生长活性下降,立即手术可能过早。
- 基于最大径和体积的10年无增大生存率分别为86.9%和54.9%。
- 增大后仅少数患者继续快速或中度增大,部分缩小或稳定。
核心结论
- 多数PMC在增大后生长活性显著下降,增大后立即手术可能为时过早。
研究设计与样本
- 纳入824例2005至2011年开始主动监测的PMC患者,中位随访6.04年,分析最大肿瘤大小和肿瘤体积变化,定义增大点(PE)为最大径增加≥3 mm(PE-M)或体积增加≥50%(PE-V),比较PE前后肿瘤倍增速率(TDR)。
主要发现
- 基于最大径和体积的10年无增大生存率分别为86.9%和54.9%。
- PE-M后TDR中位数显著低于PE前(-0.091/年 vs. 0.509/年,p < 0.001)。
- PE-V后TDR中位数显著低于PE前(-0.058/年 vs. 0.370/年,p < 0.001)。
- PE-M后仅6例(7.7%)继续快速增大(TDR >0.5/年),10例(12.8%)中度增大(TDR 0.1-0.5/年),37例(47.4%)缩小(TDR < -0.1/年),25例(32.1%)稳定(TDR介于0.1/年与-0.1/年之间)。
- PE-V后仅11例(3.8%)继续快速增大(TDR >0.5/年),35例(12.1%)中度增大(TDR 0.1-0.5/年),105例(36.1%)缩小(TDR < -0.1/年),140例(48.1%)稳定(TDR介于0.1/年与-0.1/年之间)。
临床怎么用
- 对于主动监测中增大的PMC,可考虑继续观察而非立即手术,因多数肿瘤增大后生长活性下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Although papillary thyroid microcarcinoma (PMC) is generally stable on active surveillance, conversion surgery is recommended for enlarging tumors. However, it remains unclear which enlargement threshold should be considered sufficient to trigger surgery. This study analyzed changes in the growth activity of PMC, before and after enlargement. Methods: We enrolled 824 patients with PMC, in whom active surveillance was initiated between 2005 and 2011 (median duration of follow-up: 6.04 years). Changes in the maximal tumor size and tumor volume were evaluated. Point of enlargement (PE) was defined as the time at which maximal tumor size or tumor volume had increased by ≥3 mm (PE-M) or by ≥50% (PE-V), respectively. In patients with PMC who underwent at least three ultrasound examinations during the study period, we compared the tumor doubling rates (TDRs, designated as the inverse of doubling time) between pre- and post-PEs. Results: Ten-year enlargement-free survival rates based on maximal tumor size and tumor volume were 86.9% and 54.9%, respectively. The median post-PE TDRs was significantly lower than that of pre-PEs (-0.091/year vs. 0.509/year [p < 0.001] for PE-M, and -0.058/year vs. 0.370/year [p < 0.001] for PE-V), indicating decreased tumor growth after PEs. After PE-M and PE-V, the PMCs continued to rapidly enlarge (TDR >0.5/year) in only 6 (7.7%) and 11 (3.8%) patients and moderately enlarge (TDR 0.1-0.5/year) in 10 (12.8%) and 35 (12.1%) patients, respectively. Conversely, tumors shrank (TDR < -0.1/year) in 37 (47.4%) and 105 (36.1%) patients, respectively, and remained stable (TDR ranged between 0.1/year and -0.1/year) in 25 (32.1%) and 140 (48.1%) patients, respectively. Conclusion: Since most PMCs demonstrate a significant decrease in growth activity after enlargement, performing surgery immediately after the PE may be premature.
引用
- Ito Y, Miyauchi A, Kudo T, et al. Kinetic Analysis of Growth Activity in Enlarging Papillary Thyroid Microcarcinomas. Thyroid. 2019. PMID: 31650907. doi:10.1089/thy.2019.0396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。